Recent Articles By The Author
Both names should see growth in 2023 and they're reasonably valued.
After more than a decade of historically low to near zero interest rates, cash has value again.
The nice start for the market in 2023 will soon fade.
This huge exodus shows no signs of slowing down any time soon.
Let's see how to trade GlycoMimetics, a clinical-stage drug developer focused on a type of cancer treatment.